Global /Australia /Healthcare /Biotechnology /OPT

Opthea Ltd.

OPT

• ASX: OPT • Delayed

0.6000AUD 0%

0.4282 USD

As of 6 June 2026, Opthea Ltd. has a market cap of $15.62M USD, ranking #38725 globally and #1177 in Australia. It ranks #3456 in the Healthcare sector, and #676 in the Biotechnology industry.

Global Rank

38725

Country Rank

1177

Sector Rank

3456

Industry Rank

676

Key Stats

Market Cap

$15.62MUSD

21.89M AUD

Enterprise Value

$631.96MUSD

885.55M AUD

Revenue (TTM)

-$14.36KUSD

-20.12K AUD

EBITDA (TTM)

-$78.07MUSD

-109.39M AUD

Net Income (TTM)

$211.93MUSD

296.97M AUD

PE Ratio

2.6

PS Ratio

-36723.8

PB Ratio

21.9

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Biotechnology

CEO

Jeremy Levin open_in_new

Employees

Founded

1984

Website

opthea.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-16%	-41%	-4.8%	-2.4%	-26%	-4%	-29%	-74%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	OPT Opthea Ltd ISIN: AU000000OPT2 Shares Out.: Shares Outstanding: 1.368B¹ Shares Float: 1.258B² TV: TradingView: ASX: OPT SA: Stock Analysis: ASX: OPT YF: Yahoo Finance: OPT.AX GF: Google Finance: ASX: OPT BA: Barron's: OPT MS: Morningstar: XASX: OPT	0.6000 AUD	TV: TradingView: ASX: OPT SA: Stock Analysis: ASX: OPT YF: Yahoo Finance: OPT.AX GF: Google Finance: ASX: OPT BA: Barron's: OPT MS: Morningstar: XASX: OPT
NASDAQ MIC: XNAS	OPT Opthea Ltd ADR ISIN: US68386J2087 TV: TradingView: NASDAQ: OPT SA: Stock Analysis: NASDAQ: OPT YF: Yahoo Finance: OPT GF: Google Finance: NASDAQ: OPT NQ: NASDAQ: OPT BA: Barron's: OPT MS: Morningstar: XNAS: OPT	3.41 USD	TV: TradingView: NASDAQ: OPT SA: Stock Analysis: NASDAQ: OPT YF: Yahoo Finance: OPT GF: Google Finance: NASDAQ: OPT NQ: NASDAQ: OPT BA: Barron's: OPT MS: Morningstar: XNAS: OPT
OTC Markets (OTCMKTS / OTC) MIC: OTCM	OPTEY Opthea Ltd ADR ISIN: US68386J2087 TV: TradingView: OTC: OPTEY SA: Stock Analysis: OTC: OPTEY YF: Yahoo Finance: OPTEY GF: Google Finance: OTCMKTS: OPTEY BA: Barron's: OPTEY MS: Morningstar: PINX: OPTEY	0.0400 USD	TV: TradingView: OTC: OPTEY SA: Stock Analysis: OTC: OPTEY YF: Yahoo Finance: OPTEY GF: Google Finance: OTCMKTS: OPTEY BA: Barron's: OPTEY MS: Morningstar: PINX: OPTEY

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Opthea Ltd.

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

Similar Companies

Industry: Biotechnology (Australia)

Name	Market Cap (USD) diff.	PE	Country
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 275K%	29.3	Australia
Telix Pharmaceuticals Ltd. ASX: TLX	$3.63B 5.09B AUD 23K%	-	Australia
Mesoblast Ltd. ASX: MSB	$2.05B 2.88B AUD 13K%	-	Australia
PolyNovo Ltd. ASX: PNV	$497.94M 697.75M AUD 3K%	71.8	Australia
Kazia Therapeutics Ltd. NASDAQ: KZIA	$141.64M 807%	-	Australia
Immutep Ltd. ASX: IMM	$66.26M 92.84M AUD 324%	-	Australia

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 1M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 1M%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 308K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 285K%	35.5	South Korea
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 273K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$27.89B 42.76T KRW 178K%	43.8	South Korea

chevron_leftBack